Advanced Delivery Systems for Telomere-Targeting Nucleic Acid Therapeutics
DOI:
https://doi.org/10.61173/mbpp4946Keywords:
Telomere targeting, Nucleic acid therapeutics, Drug delivery systems, Chemical modification, NanocarriersAbstract
Nucleic acid therapeutics can provide precise sequence programmability for cancer and aging-related telomeres and telomerase, but their clinical translation is still severely limited due to rapid nuclease degradation, endosomal trapping and mainly the nuclear barrier. This paper systematically reviews the landscape of delivery methods designed to overcome these physiological barriers and seeks to bridge the gap from molecular design in the laboratory to actual in vivo proof of concept in animal models. Foundational chemical changes like Phosphorothioate backbones and Locked Nucleic Acids are seen as crucial for enhancing stability and binding affinity. In addition to this, viral vectors, LNPs (Lipid Nanoparticles), polymeric systems, etc., different kinds of carrier platforms are also analyzed for observing the overall performance of this system to obtain balanced results with regard to efficiency of nuclear transduction, safety, and manufacturing scale. This paper emphasizes focusing on synergy, using “stealth” carriers for systemic circulation with specific nuclear localization signals (NLS) so that the payload is deposited at the chromosomal ends. This paper aims to summarize current progress on the adaptation relationships between delivery routes and telomere-specific demands and to offer a reference on how to choose an appropriate delivery strategy for oncology and regenerative medicine.
References
[1] Kulkarni, J.A., Witzigmann, D., Thomson, S.B., et al. (2021) ‘The current landscape of nucleic acid therapeutics’, Nature Nanotechnology, 16, pp. 630–643.
[2] Roberts, T.C., Langer, R. and Wood, M.J.A. (2020) ‘Advances in oligonucleotide drug delivery’, Nature Reviews Drug Discovery, 19, pp. 673–694.
[3] Bavelaar, B.M., Lee, B.Q., Williams, M.R., et al. (2021) ‘Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides’, Molecular Pharmaceutics, 18(10), pp. 3782-3795.
[4] Springer, A.D. and Dowdy, S.F. (2018) ‘GalNAcsiRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics’, Nucleic Acid Therapeutics, 28(3), pp. 109-118. Dean&Francis ISSN 2959-409X
[5] Uppada, S.B., Erickson, A.I., Wojdyla, L., et al. (2014) ‘Elucidating the mechanism of action of T-oligo in inhibiting melanoma cell proliferation and inducing apoptosis’, International Journal of Nanomedicine, 9, pp. 3437-3449.
[6] Nair, J.K., Willoughby, J.L., Chan, A., et al. (2014) ‘Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing’, Journal of the American Chemical Society, 136(49), pp. 16958- 16961.
[7] Tenchov, R., Bird, R., Curtze, A.E., et al. (2021) ‘Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement’, ACS Nano, 15(11), pp. 16982–17015.
[8] Patel, S., Ashwanikumar, N., Sun, E., et al. (2017) ‘Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA’, Nano Letters, 17(9), pp. 5711–5718.
[9] Cheng, Q., Wei, T., Farbiak, L., et al. (2020) ‘Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing’, Nature Nanotechnology, 15, pp. 313–320.
[10] Busatto, S., Morad, G., Guo, P., et al. (2020) ‘Polymer-based delivery of therapeutic nucleic acids: overcoming the barriers’, Molecular Therapy, 28(8), pp. 1765–1782.
[11] Ghareghomi, S., Moosavian, S.A., Rahmati, M., et al. (2021) ‘Co-delivery of hTERT siRNA and wortmannin by PLGA/chitosan nanoparticles for ovarian cancer therapy’, Life Sciences, 270, p. 119129.
[12] Bulcha, J.T., Wang, Y., Ma, H., et al. (2021) ‘Viral vector platforms within the gene therapy landscape’, Signal Transduction and Targeted Therapy, 6, p. 53.
[13] Wang, H., Liu, Y., Li, Z., et al. (2015) ‘Mannan-modified adenovirus encoding VEGFR-2 and TERT elicits potent antitumor immunity’, Cancer Immunology, Immunotherapy, 64, pp. 935–945.
[14] Shirley, J.L., de Jong, Y.P., Terhorst, C., et al. (2020) ‘Immune responses to viral gene therapy vectors’, Molecular Therapy, 28(3), pp. 709–722.
[15] Poon, W., Zhang, Y.N., Ouyang, B., et al. (2019) ‘Elimination pathways of nanoparticles’, ACS Nano, 13(5), pp. 5785–5798.
[16] Hua, Y., Wu, M., Zhang, Y., et al. (2021) ‘Poly(lactic-coglycolic acid) microsphere production based on microfluidics for drug delivery’, Drug Delivery, 28(1), pp. 1386-1398.
[17] Teo, S.L.Y., Birkenfeld, K., Cohen, J., et al. (2021) ‘Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay’, Nature Communications, 12, p. 3721.
[18] Beach, M.A., Zhang, X. and Zhang, Y. (2022) ‘Quantifying the Endosomal Escape of pH-Responsive Nanoparticles Using the Split Luciferase Endosomal Escape Quantification Assay’, ACS Applied Materials & Interfaces, 14(3), pp. 3653-3661.
[19] Ding, H. and Wu, F. (2012) ‘Image Guided Biodistribution and Pharmacokinetic Studies of Theranostics’, Theranostics, 2(11), pp. 1040-1053
Downloads
Published
Issue
Section
License
Copyright (c) 2026 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
